TUSTIN, Calif., April 10 /PRNewswire/ -- Oncotech is the leading company in providing critical cellular and genomic information to oncologists throughout the United States to assist them in matching individualized tumor biology to the most appropriate chemotherapy. At the March 2006 German Cancer Congress in Berlin, Oncotech announced the collaboration with TherapySelect to market Oncotech's cancer testing services in Germany. As a result of the collaboration, German physicians and their cancer patients will be able to benefit from Oncotech's cancer testing services.
In Germany, the overall incidence for cancer is about 400,000 patients per year. Oncotech is pleased to be able to work with TherapySelect, a biomedical laboratory located in Heidelberg, to offer state-of-the-art cancer diagnostic tests to cancer patients throughout Germany. Oncotech's assays are already well-received in the United States where over 5,000 physicians and more than 1,000 hospitals have already utilized Oncotech's cancer testing services.
"New molecular technologies allow us to identify unique cellular and genetic factors in cancer patients," states Mr. Frank J. Kiesner, President and CEO of Oncotech, "when properly employed, these technologies can assist oncologists throughout the world to better match chemotherapeutic alternatives to the needs of their cancer patients. Oncotech's cancer testing services allow physicians to identify drug resistance and modify treatment options as they deem appropriate for each individual cancer patient. We are most pleased to work with TherapySelect in Germany."
Dr. Ragen Pfeiffer, Managing Partner, TherapySelect, commented, "Regarding the clinical development of the EDR Assay and other Oncotech cancer testing services, TherapySelect is optimistic to be able to support Oncotech's activities with its strong network among German opinion leaders in oncology. TherapySelect is proud to represent Oncotech in Germany. Their reputation for quality and service is excellent."
Oncotech is a company dedicated to improving the survival and quality of life of cancer patients through its molecular oncology testing services as well as through genomic research leading to the discovery and development of new pharmaceutical products. Oncotech provides testing services to over one thousand hospitals in the U.S. and works with major pharmaceutical companies throughout the world to assist them in the development of new targeted drugs. Oncotech is a market leader in the field of in vitro drug resistance and therapy selection testing. More information on the company is available at www.oncotech.com.
TherapySelect develops and distributes cancer diagnostics to prolong life of cancer patients and to improve quality of life. For this purpose, TherapySelect cooperates with the market leader in chemoresistance testing in the USA, Oncotech, Inc. TherapySelect distributes Oncotech products, the EDR Assay and other services, exclusively in Germany. More information on the company is available at www.therapyselect.de.
CONTACT: Frank J. Kiesner, President and Chief Executive Officer ofOncotech Inc., +1-800-576-6326; or Ragen Pfeiffer, M.D., Managing Partnerof TherapySelect GmbH & Co., +49 (0) 6221-8936-152